Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Prospective Randomized Trial of an Adjuvant Therapy of Completely Resected Merkel Cell Carcinoma (MCC) With Immune Checkpoint Blocking Antibodies (Nivolumab, Opdivo®; Ipilimumab (Yervoy®) Every 3 Weeks for 12 Weeks Versus Observation

NCT02196961 is registered in ClinicalTrials.gov with Prof. Dr. med. Dirk Schadendorf as lead sponsor.

NCT NCT02196961
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02196961 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Prospective Randomized Trial of an Adjuvant Therapy of Completely Resected Merkel Cell Carcinoma (MCC) With Immune Checkpoint Blocking Antibodies (Nivolumab, Opdivo®; Ipilimumab (Yervoy®) Every 3 Weeks for 12 Weeks Versus Observation
Lead sponsor
Prof. Dr. med. Dirk Schadendorf
Phase
Phase 2
Overall status
Completed
Start date
June 30, 2014
Completion date
August 31, 2024
Enrollment
180 (actual)
Sites
20

Conditions

As the registry lists them; a condition with its own page is linked.

merkel cell carcinoma